Description: Rapid Direct Sequencing Analysis of Clinical Samples using NGS or Sanger. Less than 5 minutes analysis time. No bioinformatics resources needed.
hiv (784) patient (690) identification (365) bacteria (281) hpv (179) hla (44) direct sequencing analysis identification mixed clinical samples (6) direct sequencing analysis (5) mixed clinical samples (5) dual loci (5)
Pathogenomix Inc., a Next Generation Sequencing, pathogen diagnostic company, is announcing that the US Food and Drug Administration (FDA) has granted it a Breakthrough Device Designation for its Patho-Seq assay.
Ripseq sequence-based analysis reduces the time needed to identify infectious pathogens, in pure- or poly-microbial samples, by up to 90% - and provides answers where other methods fail. Use any sequencing technology you want - Ripseq is platform agnostic.
Combined with Ripseq DB, this is complete SaaS diagnostic solution, able to identify pathogens more accurately, faster and at lower cost than current methods.